Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist

被引：2

作者：

Baska, Ferenc ^{[1
]}

Bozo, Eva ^{[1
]}

Szeleczky, Zsolt ^{[1
]}

Szanto, Gabor ^{[1
]}

Vukics, Krisztina ^{[1
]}

Szakacs, Zoltan ^{[1
]}

Domany-Kovacs, Katalin ^{[1
]}

Kurko, Dalma ^{[1
]}

Vass, Elemer ^{[2
]}

Than, Marta ^{[1
]}

Vastag, Monika ^{[1
]}

Temesvari, Krisztina ^{[1
]}

Levai, Sandor ^{[1
]}

Halasz, Attila Sandor ^{[1
]}

Kordas, Krisztina Szondine ^{[1
]}

Roman, Viktor ^{[1
]}

Greiner, Istvan ^{[1
]}

Bata, Imre ^{[1
]}

机构：

[1] Gedeon Richter Plc, H-1475 Budapest, Hungary

[2] Eotvos Lorand Univ, Inst Chem, H-1117 Budapest, Hungary

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 01期

关键词：

RANDOMIZED CONTROLLED-TRIAL; AUTISM SPECTRUM DISORDERS; VASOPRESSIN V1A; ACTIVE METABOLITE; BALOVAPTAN; PHARMACOKINETICS; PAZINACLONE; INHIBITION; SR-49059; SINGLE;

D O I：

10.1021/acs.jmedchem.3c01868

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The V1a receptor is a major contributor in mediating the social and emotional effects of arginine-vasopressin (AVP); therefore it represents a promising target in the treatment of several neuropsychiatric conditions. The aim of this research was to design and synthesize novel and selective V1a antagonists with improved in vitro and in vivo profiles. Through optimization and detailed SAR studies, we developed low nanomolar antagonists, and further characterizations led to the discovery of the clinical candidate compound 43 (RGH-122). The CNS activity of the compound was determined in a 3-chamber social preference test of autism in which RGH-122 successfully enhanced social preference with the lowest effective dose of 1.5 mg/kg.

引用

页码：643 / 673

页数：31

共 50 条

[1] Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist
Arbuckle, William
Baker, James
Barn, David
Bingham, Matilda
Brown, Angus
Buchanan, Kirsteen
Craighead, Mark
Goodwin, Richard
Goutcher, Susan
Kiczun, Michael
Lyons, Amanda
Milne, Rachel
Montgomery, Brian
Napier, Susan
Presland, Jeremy
Sloan, Hazel
Turnbull, Zara
Wishart, Grant
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (15) : 4622 - 4628
[2] Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
Scott, James S.
Moss, Thomas A.
Balazs, Amber
Barlaam, Bernard
Breed, Jason
Carbajo, Rodrigo J.
Chiarparin, Elisabetta
Davey, Paul R. J.
Delpuech, Oona
Fawell, Stephen
Fisher, David, I
Gagrica, Sladjana
Gangl, Eric T.
Grebe, Tyler
Greenwood, Ryan D.
Hande, Sudhir
Hatoum-Mokdad, Holia
Herlihy, Kara
Hughes, Samantha
Hunt, Thomas A.
Hoan Huynh
Janbon, Sophie L. M.
Johnson, Tony
Kavanagh, Stefan
Klinowska, Teresa
Lawson, Mandy
Lister, Andrew S.
Marden, Stacey
McGinnity, Dermot F.
Morrow, Christopher J.
Nissink, J. Willem M.
O'Donovan, Daniel H.
Peng, Bo
Polanski, Radoslaw
Stead, Darren S.
Stokes, Stephen
Thakur, Kumar
Throner, Scott R.
Tucker, Michael J.
Varnes, Jeffrey
Wang, Haixia
Wilson, David M.
Wu, Dedong
Wu, Ye
Yang, Bin
Yang, Wenzhan
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (23) : 14530 - 14559
[3] Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist
De Savi, Chris
Bradbury, Robert H.
Rabow, Alfred A.
Norman, Richard A.
Buttar, David
Currie, Gordon S.
Weir, Hazel
Donald, Craig
Andrews, David
MacFaul, Phil
Ballard, Peter
Curwen, Jon
Wilson, Zena
Richmond, Graham
D'Cruz, Celina
Powell, Steve
Walker, Graeme
Hulse, Michael
Tonge, Michael
CANCER RESEARCH, 2015, 75
[4] Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist
Bell, Ian M.
Gallicchio, Steven N.
Wood, Michael R.
Quigley, Amy G.
Stump, Craig A.
Zartman, C. Blair
Fay, John F.
Li, Chi-Chung
Lynch, Joseph J.
Moore, Eric L.
Mosser, Scott D.
Prueksaritanont, Thomayant
Regan, Christopher P.
Roller, Shane
Salvatore, Christopher A.
Kane, Stefanie A.
Vacca, Joseph P.
Selnick, Harold G.
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (01): : 24 - 29
[5] Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist
Hoashi, Yasutaka
Takai, Takafumi
Kosugi, Yohei
Nakashima, Masato
Nakayama, Masaharu
Hirai, Keisuke
Uchikawa, Osamu
Koike, Tatsuki
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (06) : 3059 - 3074
[6] Discovery of ubrogepant (MK-1602): A potent, selective and orally bioavailable CGRP receptor antagonist for the acute treatment of migraine
Fraley, Mark
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
[7] Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists
Ward, Simon E.
Eddershaw, Peter J.
Scott, Claire M.
Gordon, Laurie J.
Lovell, Peter J.
Moore, Susan H.
Smith, Paul W.
Starr, Kathryn R.
Thewlis, Kevin M.
Watson, Jeannette M.
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (10) : 2887 - 2890
[8] Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2
Yang, Michael G.
Xiao, Zili
Zhao, Rulin
Tebben, Andrew J.
Wang, Bei
Cherney, Robert J.
Batt, Douglas G.
Brown, Gregory D.
Cvijic, Mary Ellen
Duncia, John, V
Gallela, Michael A.
Gardner, Daniel S.
Khandelwal, Purnima
Malley, Mary F.
Pang, Jian
Rose, Anne, V
Santella, Joseph B., III
Sarjeant, Amy A.
Xu, Songmei
Mathur, Arvind
Mandlekar, Sandhya
Vuppugalla, Ragini
Zhao, Qihong
Carter, Percy H.
ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (06): : 969 - 975
[9] Discovery and synthesis of a potent, selective and orally bioavailable EP4 receptor agonist
Young, RN
Billot, X
Han, YX
Slipetz, DA
Chauret, N
Belley, M
Metters, K
Mathieu, MC
Greig, GM
Denis, D
Girard, M
HETEROCYCLES, 2004, 64 : 437 - 446
[10] Discovery and optimization of potent, selective, and orally bioavailable Jak1 inhibitors
Zak, Mark
Johnson, Adam
Van Abbema, Anne
Waszkowycz, Bohdan
Eigenbrot, Charles
Chang, Christine
Hurley, Christopher
Hanan, Emily
Kenny, Jane
Kulagowski, Janusz
DeVoss, Jason
Murray, Jeremy
Balazs, Mercedesz
Steffek, Micah
Koehler, Michael
Ghilardi, Nico
Chakravarty, Paroma
Lupardus, Patrick
Gibbons, Paul
Dragovich, Peter
Bergeron, Philippe
Pulk, Rebecca
Mendonca, Rohan
Savage, Scott
Labadie, Sharada
Gradl, Stefan
Ward, Stuart
Blair, Wade
Jia, Wei
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243

← 1 2 3 4 5 →